Top News

Domain Associates, Versant Get Another IPO Exit

Two, Southern California venture investors have scored another paired exit today, after South San Francisco-based Achaogen debuted on the NASDAQ Global Market as AKAO. Both Domain Associates and Versant Ventures had an exit via another, biotech IPO-->of molecular diagnostic maker Veracyte--just six months ago. Achaogen was trading around $14.17 this afternoon, after debuting at $12.00 per share. Achaogen had set an initial IPO pricing range earlier of $10.00 to $12.00 per share. Domain Associates owned 18.7% of Achaogen before the IPO, and Versant Ventures had around 11.9% of the company. Other investors include Venrock, The Wellcome Trust, Arch Ventures Partners, Omega Fund, and 5AM Ventures.





Latest Headlines

Browse Issues


Keep up with all of the latest Southern California high tech news via email (it's free!)

or Cancel